Related Experiment Video
Updated: Apr 3, 2026

06:25
Fabrication of a Master Mold for Microneedles with a Micron-sized Air-vent Hole
Published on: December 5, 2025
546
Technical challenges and quality considerations for dissolving microneedles
Nahid S Kamal1, Samuel Acheampong1, Rokon Uz Zaman1
1Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality (OPQ), CDER, FDA, USA.
International Journal of Pharmaceutics
|April 1, 2026
Summary
Optimizing polyvinyl alcohol (PVA) concentration in dissolving microneedles (DMNs) enhances structural integrity and controls drug release. The polymer-to-API ratio impacts drug distribution and release kinetics for improved transdermal delivery systems.
Area of Science:
- Pharmaceutical Sciences
- Biomaterials Engineering
- Drug Delivery Systems
Background:
- Dissolving microneedles (DMNs) offer transdermal drug delivery by penetrating the stratum corneum.
- Challenges exist in optimizing DMN formulations for mechanical properties and drug release.
- Lack of standardized quality control hinders DMN product development.
Purpose of the Study:
- To investigate testing methods for DMNs.
- To evaluate the impact of polymer-to-API ratio on DMN critical quality attributes (CQAs).
- To understand how CQAs influence drug release and skin permeation.
Main Methods:
- DMNs formulated with varying polyvinyl alcohol (PVA) concentrations and metoprolol succinate.
- Microscopic imaging with AI segmentation for morphological analysis.
- Intensity-distance analysis for drug distribution assessment.
- Mechanical testing (fracture force) and in vitro drug release/permeation studies.
Main Results:
- Pyramidal DMNs with consistent dimensions were successfully fabricated.
- Increased PVA content enhanced microneedle fracture force and structural integrity.
- Polymer-to-API ratio did not affect skin insertion or disintegration.
- Higher PVA content slowed drug release, identifying polymer as a key release controller.
- Drug permeation correlated with spatial drug distribution within the microneedles.
Conclusions:
- Optimizing the PVA-to-drug ratio is crucial for controlling DMN drug release and permeation.
- Controlling drug distribution within DMNs is essential for enhancing transdermal delivery performance.
- Standardized testing methods are needed to address quality control challenges in DMN development.

